Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD, MaxCmin2 Trial Group: A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005, 10: 735-743.
CAS
PubMed
Google Scholar
Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F: Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009, 50: 367-374. 10.1097/QAI.0b013e318198a815
Article
PubMed
Google Scholar
Roche Pharmaceuticals Invirase Prescribing Information, July. Accessed: 20 Jan 2010.http://www.rocheusa.com/products/invirase/pi.pdf
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2009, 1-161. Accessed: 15 Jan 2010.http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
Google Scholar
Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P: Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther. 2004, 9: 247-256.
CAS
PubMed
Google Scholar
Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P: The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Med. 2005, 6: 122-128. 10.1111/j.1468-1293.2005.00274.x
Article
CAS
PubMed
Google Scholar
Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group: Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 2008, 13: 375-380.
CAS
PubMed
Google Scholar
Montaner JS, Schutz M, Schwartz R, Jayaweera DT, Burnside AF, Walmsley S, Saag MS: Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed. 2006, 8: 36-
PubMed Central
PubMed
Google Scholar
López-Cortés LF, Ruiz-Valderas R, Viciana P, Mata R, Gómez-Vera J, Alarcón A, Pachón J: Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. J Acquir Immune Defic Syndr. 2003, 32: 240-2.
Article
PubMed
Google Scholar
Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M: Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2007, 51: 2035-2042. 10.1128/AAC.01136-06
Article
PubMed Central
CAS
PubMed
Google Scholar
Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A: Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit. 2007, 29: 171-176. 10.1097/FTD.0b013e31803bb54e
Article
CAS
PubMed
Google Scholar
Knechten H, Stephan C, Lutz T, Stoehr A, Carganico A, Knecht G, Schewe K, Jaeger H, Mayr C, Mosthaf FA, Wolf E, Wellmann E, Tappe A: The Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients - 48-week results from Germany. J Int AIDS Soc. 2008, 11 (Suppl 1): P13-10.1186/1758-2652-11-S1-P13.
Article
Google Scholar
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD: Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005, 13: 125-131.
PubMed
Google Scholar
Kurowski M, Müller M, Donath F, Mrozikiewicz M, Möcklinghoff C: Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. Eur J Med Res. 1999, 4: 101-104.
CAS
PubMed
Google Scholar
van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM: Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. AIDS. 2000, 14: F103-110. 10.1097/00002030-200006160-00003
Article
CAS
PubMed
Google Scholar
Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS: Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 2000, 44: 2672-2678. 10.1128/AAC.44.10.2672-2678.2000
Article
PubMed Central
CAS
PubMed
Google Scholar
Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P: Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J Acquir Immune Defic Syndr. 2003, 32: 375-379. 10.1097/00126334-200304010-00005
Article
CAS
PubMed
Google Scholar
Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A: Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther. 2004, 9: 423-429.
CAS
PubMed
Google Scholar
Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D: Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother. 2004, 54: 785-790. 10.1093/jac/dkh415
Article
CAS
PubMed
Google Scholar
Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A: Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004, 48: 2388-2393. 10.1128/AAC.48.7.2388-2393.2004
Article
PubMed Central
CAS
PubMed
Google Scholar
Gieschke R, Fotteler B, Buss N, Steimer JL: Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 1999, 37: 75-86. 10.2165/00003088-199937010-00005
Article
CAS
PubMed
Google Scholar
Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B, SQV-HEP Study Group: Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. Antimicrob Chemother. 2009, 63: 992-7. 10.1093/jac/dkp070.
Article
Google Scholar
Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG: The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol. 2004, 44: 293-304. 10.1177/0091270003262956
Article
CAS
PubMed
Google Scholar
Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X: Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addict Biol. 2009, 14: 321-7. 10.1111/j.1369-1600.2009.00158.x
Article
CAS
PubMed
Google Scholar